Dimensional Fund Advisors LP Trims Holdings in Prestige Consumer Healthcare Inc. (NYSE:PBH)

Dimensional Fund Advisors LP decreased its stake in shares of Prestige Consumer Healthcare Inc. (NYSE:PBH) by 1.8% during the fourth quarter, according to its most recent filing with the SEC. The institutional investor owned 2,907,066 shares of the company’s stock after selling 51,952 shares during the period. Dimensional Fund Advisors LP owned 5.88% of Prestige Consumer Healthcare worth $227,011,000 as of its most recent SEC filing.

Several other large investors have also added to or reduced their stakes in the stock. Kestra Investment Management LLC bought a new position in shares of Prestige Consumer Healthcare in the fourth quarter valued at approximately $27,000. CIBC Private Wealth Group LLC raised its position in shares of Prestige Consumer Healthcare by 48.9% in the fourth quarter. CIBC Private Wealth Group LLC now owns 463 shares of the company’s stock worth $34,000 after buying an additional 152 shares in the last quarter. Headlands Technologies LLC bought a new stake in Prestige Consumer Healthcare during the fourth quarter valued at $40,000. GAMMA Investing LLC increased its stake in Prestige Consumer Healthcare by 18.9% in the 4th quarter. GAMMA Investing LLC now owns 1,383 shares of the company’s stock worth $108,000 after acquiring an additional 220 shares during the last quarter. Finally, Huntington National Bank raised its holdings in shares of Prestige Consumer Healthcare by 133.2% in the 4th quarter. Huntington National Bank now owns 1,481 shares of the company’s stock valued at $116,000 after acquiring an additional 846 shares in the last quarter. Institutional investors own 99.95% of the company’s stock.

Insiders Place Their Bets

In other news, SVP Mary Beth Fritz sold 1,678 shares of the stock in a transaction dated Monday, March 10th. The shares were sold at an average price of $90.00, for a total transaction of $151,020.00. Following the completion of the sale, the senior vice president now directly owns 17,157 shares in the company, valued at approximately $1,544,130. This represents a 8.91 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Insiders own 1.60% of the company’s stock.

Prestige Consumer Healthcare Trading Down 2.1 %

NYSE PBH opened at $78.62 on Tuesday. The firm has a market cap of $3.89 billion, a PE ratio of 18.41, a price-to-earnings-growth ratio of 2.69 and a beta of 0.47. Prestige Consumer Healthcare Inc. has a 1-year low of $62.35 and a 1-year high of $90.04. The stock has a 50-day moving average of $84.04 and a 200-day moving average of $80.31. The company has a current ratio of 3.68, a quick ratio of 2.20 and a debt-to-equity ratio of 0.56.

Prestige Consumer Healthcare (NYSE:PBH) last announced its quarterly earnings data on Thursday, February 6th. The company reported $1.22 earnings per share for the quarter, beating the consensus estimate of $1.18 by $0.04. Prestige Consumer Healthcare had a return on equity of 12.36% and a net margin of 19.13%. As a group, sell-side analysts forecast that Prestige Consumer Healthcare Inc. will post 4.5 EPS for the current year.

Analyst Ratings Changes

Several research analysts recently weighed in on PBH shares. Royal Bank of Canada upped their price objective on shares of Prestige Consumer Healthcare from $96.00 to $97.00 and gave the stock a “sector perform” rating in a research report on Friday, March 21st. Oppenheimer increased their target price on Prestige Consumer Healthcare from $87.00 to $93.00 and gave the company an “outperform” rating in a research note on Thursday, February 13th. StockNews.com lowered Prestige Consumer Healthcare from a “buy” rating to a “hold” rating in a research note on Tuesday, April 8th. Canaccord Genuity Group increased their price objective on Prestige Consumer Healthcare from $93.00 to $100.00 and gave the company a “buy” rating in a research report on Friday, February 7th. Finally, DA Davidson boosted their target price on Prestige Consumer Healthcare from $95.00 to $104.00 and gave the stock a “buy” rating in a research report on Friday, February 7th. Four analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Hold” and an average price target of $93.33.

Prestige Consumer Healthcare Company Profile

Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.